Evaluation of safety and therapeutic efficacy of a siddha herbomineral formulation KANDAAMALAGA ILAKAM (Internal) in the treatment of AZHAL VELUPPU NOI (Iron deficiency anaemia) - KANDAAMALAGA ILAKAM

Ayothidoss Pandithar Hospital0 sites0 target enrollmentTBD

ConditionsHealth Condition 1: null- patients complaints with pallor of skin and mucus membrane, fatigue, lassitude,chest discomfort, breathlessness,pica,giddiness,dizziness,angular stomatitis, pungent or bitter taste.

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Health Condition 1: null- patients complaints with pallor of skin and mucus membrane, fatigue, lassitude,chest discomfort, breathlessness,pica,giddiness,dizziness,angular stomatitis, pungent or bitter taste.
Sponsor: Ayothidoss Pandithar Hospital
Status: Not yet recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional

Investigators

Sponsor

Ayothidoss Pandithar Hospital

Eligibility Criteria

Inclusion Criteria

•Hb level less than normal range, For male:7\-10gms/dl(normal:13\-18gms/dl),For female:7\-10gms/dl(normal:11\.5\-16\.5\), patient willing to undergo blood investigation, patient who are willing to participate in study and signing in informed consent form.

Exclusion Criteria

•Hypertention, presence of any associated severe systemic illness (Eg.cancer, rheumatoid), Endocrine disorder( thyroid abnormality, diabetes mellitus), severe cardiac disease,Inherited defects(sickle cell Anemia, Thalassemia, Aplastic anaemia), patient not willing to give blood sample

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Phase 2

A study on siddha medicine kumaara veeriya kaantha chenduram for anaemiaHealth Condition 1: D508- Other iron deficiency anemias

CTRI/2019/04/018795Ayothidoss Pandithar hospital30

Completed

Phase 4

Evaluation of therapeutic efficacy and safety of artesunate-amodiaquine, artemether-lumefantrine and dihydroartemisinine-piperaquine for the treatment of uncomplicated Plasmodium falciparum in Democratic Republic of CongoMalariaInfection - Studies of infection and infectious agents

ACTRN12616001423404Ministry of Health534

Active, not recruiting

Phase 1

Study of the safety and effectiveness of drug AZD4017 at reducing pressure in the brain, in idiopathic intracranial hypertension.Idiopathic Intracranial HypertensionMedDRA version: 18.0Level: PTClassification code 10004277Term: Benign intracranial hypertensionSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]

EUCTR2013-003643-31-GBniversity of Birmingham30

Recruiting

Phase 1

Itolizumab (T1h) combined with insulin in patients with Type I Diabetes MellitusType 1 diabetes mellitusDiabetes Mellitus, Type 1Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

RPCEC00000225Center of Molecular Immunology (CIM)40

Not yet recruiting

Phase 2

VALERGEN-combination of routes- Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental Illness

RPCEC00000298ational Center of Bioproducts (BioCen)180